capecitabine has been researched along with Mesothelioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kosuri, KV; Otterson, GA; Villalona-Calero, MA; Wang, L; Wu, X | 1 |
| Green, MR; Herndon, JE; Kindler, HL; Otterson, GA; Watson, D | 1 |
1 trial(s) available for capecitabine and Mesothelioma
| Article | Year |
|---|---|
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Treatment Outcome | 2004 |
1 other study(ies) available for capecitabine and Mesothelioma
| Article | Year |
|---|---|
An epigenetic mechanism for capecitabine resistance in mesothelioma.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; CpG Islands; Deoxycytidine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Pericardium; Promoter Regions, Genetic; Sequence Analysis, DNA; Thymidine Phosphorylase | 2010 |